Reports
Sale
Laryngeal Cancer Therapeutics Market Size, Trends, Report: By Product Type: Biologics, Small Molecules; By Treatment Type: Radiation Therapy, Chemotherapy, Immunotherapy, Others; By Route of Administration: Oral, Parenteral, Topical; By Stage; By End User; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032
Laryngeal Cancer Therapeutics Market Outlook
The laryngeal cancer therapeutics market size in the 7 major regions was valued at USD 4.1 billion in 2023, driven by the increasing incidence of laryngeal cancer across these regions. The market size is anticipated to grow at a CAGR of 4.20% during the forecast period of 2024-2032 to achieve a value of USD 5.9 billion by 2032.
Laryngeal Cancer Therapeutics: Introduction
Laryngeal cancer, which affects the voice box or larynx, presents symptoms that can often be mistaken for other conditions, making early diagnosis crucial. The most common sign is persistent hoarseness, sometimes misconstrued as a common cold symptom. If you notice ongoing symptoms such as a sore throat, chronic cough, voice changes lasting beyond two weeks, swallowing difficulties, a lump in the neck or throat, trouble producing voice sounds (dysphonia), or ear pain, it is essential to consult a healthcare provider for a proper diagnosis. Treatment for laryngeal cancer may involve surgical procedures like laryngectomy, which entails the removal of part or all the larynx. The risk of developing laryngeal cancer is significantly elevated by smoking or using tobacco products.
Laryngeal Cancer Therapeutics Market Analysis
Significant advancements and investments in the field are significantly propelling the laryngeal cancer therapeutics market demand. One significant trend in the market is the increased investment activities. For example, an investment of over USD 11 million by the California Institute for Regenerative Medicine (CIRM) to support a phase II clinical trial aimed at testing a cell therapy for aiding throat cancer patients in their recovery from the adverse effects of radiation therapy has taken place recently. This promising initiative is conducted by Professor Peter Belafsky, an expert in otolaryngology, who also directs the UC Davis Health Center for Voice and Swallowing.
Additionally, innovative technologies are emerging to enhance the diagnosis and treatment of laryngeal cancer further influencing the laryngeal cancer therapeutics market growth. For example, a team of students, led by a lecturer in the Department of Physics at William & Mary, is developing an advanced instrument called Britescope, designed to improve endotracheal intubation procedures. Britescope's potential for success and life-saving capabilities have garnered support from the Virginia Innovation Partnership Corporation's Commonwealth Commercialization Fund. These investments and technological innovations are driving positive trends in the laryngeal cancer therapeutics market, offering new hope for patients and improving treatment outcomes.
Laryngeal Cancer Therapeutics Market Segmentations
Market Breakup by Product Type
- Biologics
- Small Molecules
Market Breakup by Treatment Type
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
Market Breakup by Stage
- Stage 0
- Stage-I
- Stage-II
- Stage-III
- Stage-IV
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centres
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Laryngeal Cancer Therapeutics Market Overview
The market is witnessing significant growth driven by several key factors. For example, according to the latest estimates from the American Cancer Society, there are expected to be about 12,380 new cases of laryngeal cancer in the United States in 2023, indicating a rising prevalence of neck and head cancers. This surge in cases is fuelling the demand for combination therapies to effectively treat these cancers expected to contribute to the market growth.
Moreover, substantial growth in research and development activities aimed at developing innovative cancer therapeutics is also contributing to the laryngeal cancer therapeutics market growth. The increasing adoption of head and neck cancer therapeutics is also acting as a major driver, which is propelled by the urgent need for more effective treatments.
North America is currently leading the regional market due to the high number of head and neck cancers in the region. Regional market players are actively engaging in product launches, mergers, and acquisitions to establish a significant presence in the market to further boost market growth. Additionally, the presence of well-developed healthcare infrastructure and the active involvement of various government organizations in addressing the mounting burden of head and neck cancer are further propelling the regional market growth.
Laryngeal Cancer Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson Private Limited
- Cipla Inc.
- Abbott
- AbbVie Inc.
- Merck KGaA
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals LLC.
- Pfizer Inc.
- Mylan N.V.
- Bristol-Myers Squibb Company
- GSK plc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Stage |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Laryngeal Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Laryngeal Cancer Therapeutics Epidemiology Analysis-7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.1 Germany Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.2 France Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.3 Italy Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.4 Spain Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.4 Japan Laryngeal Cancer Epidemiology Forecast (2017-2032)
6 Laryngeal Cancer Treatment Market Overview – 7MM
6.1 Laryngeal Cancer Treatment Market Historical Value (2017-2023)
6.2 Laryngeal Cancer Treatment Market Forecast Value (2024-2032)
7 Laryngeal Cancer Therapeutics Market Landscape
7.1 Laryngeal Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Laryngeal Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Laryngeal Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Laryngeal Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Laryngeal Cancer Therapeutics Market Segmentation-7MM
11.1 Laryngeal Cancer Therapeutics Market by Product Type
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Small Molecules
11.2 Laryngeal Cancer Therapeutics Market by Treatment Type
11.2.1 Market Overview
11.2.2 Radiation Therapy
11.2.3 Chemotherapy
11.2.4 Immunotherapy
11.2.5 Others
11.3 Laryngeal Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Topical
11.4 Laryngeal Cancer Therapeutics Market by Stage
11.4.1 Market Overview
11.4.2 Stage 0
11.4.3 Stage-I
11.4.4 Stage-II
11.4.5 Stage-III
11.4.6 Stage-IV
11.5 Laryngeal Cancer Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Specialty Centres
11.5.5 Others
11.6 Laryngeal Cancer Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Retail Pharmacies
11.6.4 Online Pharmacies
11.7 Laryngeal Cancer Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan
12 United States Laryngeal Cancer Therapeutics Market
12.1 U.S. Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
12.2 U.S. Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market
13.1 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
13.2 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14 Japan Laryngeal Cancer Therapeutics Market
14.1 Japan Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
14.2 Japan Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Johnson & Johnson Private Limited
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Cipla Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Abbott
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Merck KGaA
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bausch Health Companies Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sun Pharmaceutical Industries Ltd.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Aurobindo Pharma
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Lupin
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Hikma Pharmaceuticals PLC
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amneal Pharmaceuticals LLC.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Pfizer Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Mylan N.V.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Bristol-Myers Squibb Company
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 GSK plc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Laryngeal Cancer Therapeutics - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 4.1 billion in 2023, driven by increased awareness about the importance of proper treatment.
The market is anticipated to grow at a CAGR of 4.20% during the forecast period of 2024-2032 and is likely to reach a market value of USD 5.9 billion by 2032.
The increasing adoption of head and neck cancer therapeutics across the major markets is a major factor driving the market growth.
The increase in investments made by key players in the market is a major trend influencing market growth.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. The EU-4 regions can be categorised into Germany, France, Italy, and Spain.
Various products in the market include biologics and small molecules.
Various treatments in the market include radiation therapy, chemotherapy, and immunotherapy, among others.
Various routes of administration include oral, parenteral, and topical.
Stages are as follows Stage 0, Stage-I, Stage-II, Stage-III, Stage-IV.
The end-users include hospitals, homecare, and specialty centres, among others.
Various distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., Merck KGaA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Amneal Pharmaceuticals LLC., Pfizer Inc., Mylan N.V., Bristol-Myers Squibb Company, GSK plc., and Hikma Pharmaceuticals PLC.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER